ImmuneOncia Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 25

Employees

  • Stock Symbol
  • 424870

Stock Symbol

  • Share Price
  • $1.79
  • (As of Monday Closing)

ImmuneOncia General Information

Description

Immuneoncia Therapeutics Inc is an immuno-oncology-centric biopharmaceutical company. The company focuses on developing immunotherapies for cancer treatment.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 25, Tapsil-ro 35beon-gil
  • Giheung-gu
  • Yongin, Gyeonggi 17084
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 25, Tapsil-ro 35beon-gil
  • Giheung-gu
  • Yongin, Gyeonggi 17084
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmuneOncia Stock Performance

As of 16-Nov-2026, ImmuneOncia’s stock price is $1.79. Its current market cap is $164M with 91.3M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.79 $1.84 $1.58 - $10.16 $164M 91.3M 628K -$0.26

ImmuneOncia Financials Summary

As of 30-Jun-2026, ImmuneOncia has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 199,491 647,290
Revenue 0 78 480 84
EBITDA (20,319) (19,094) (3,898) 6,982
Net Income (20,194) (19,227) (4,168) 6,780
Total Assets 68,142 23,018 17,784 26,225
Total Debt 27 48 65 106
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ImmuneOncia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ImmuneOncia‘s full profile, request access.

Request a free trial

ImmuneOncia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Immuneoncia Therapeutics Inc is an immuno-oncology-centric biopharmaceutical company. The company focuses on developing
Drug Discovery
Yongin, South Korea
25 As of 2025

Rockville, MD
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmuneOncia Competitors (22)

One of ImmuneOncia’s 22 competitors is NovaBridge Biosciences, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NovaBridge Biosciences Formerly VC-backed Rockville, MD
Altimmune Formerly VC-backed Gaithersburg, MD
Lisata Therapeutics Corporation Basking Ridge, NJ
AVEO Oncology Formerly VC-backed Boston, MA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 22 competitors. Get the full list »

ImmuneOncia Patents

ImmuneOncia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024430244-A1 Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody Active 22-May-2024
AU-2024430244-B2 Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody Active 22-May-2024
EP-4674869-A1 Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody Pending 22-May-2024
EP-4674869-A4 Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody Pending 22-May-2024
WO-2025244201-A1 Method for treatment of advanced or metastatic solid cancer using anti-cd47 antibody Pending 22-May-2024 C07K16/2803
To view ImmuneOncia’s complete patent history, request access »

ImmuneOncia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmuneOncia ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view ImmuneOncia’s complete esg history, request access »

ImmuneOncia FAQs

  • When was ImmuneOncia founded?

    ImmuneOncia was founded in 2016.

  • Where is ImmuneOncia headquartered?

    ImmuneOncia is headquartered in Yongin, South Korea.

  • What is the size of ImmuneOncia?

    ImmuneOncia has 25 total employees.

  • What industry is ImmuneOncia in?

    ImmuneOncia’s primary industry is Drug Discovery.

  • Is ImmuneOncia a private or public company?

    ImmuneOncia is a Public company.

  • What is ImmuneOncia’s stock symbol?

    The ticker symbol for ImmuneOncia is 424870.

  • What is the current stock price of ImmuneOncia?

    As of 16-Nov-2026 the stock price of ImmuneOncia is $1.79.

  • What is the current market cap of ImmuneOncia?

    The current market capitalization of ImmuneOncia is $164M.

  • Who are ImmuneOncia’s competitors?

    NovaBridge Biosciences, Altimmune, Lisata Therapeutics, AVEO Oncology, and CytomX Therapeutics are some of the 22 competitors of ImmuneOncia.

  • What is ImmuneOncia’s annual earnings per share (EPS)?

    ImmuneOncia’s EPS for 12 months was -$0.26.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process